Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2026Japanese Journal of Clinical Oncology

Prognostic significance of the FAN score in patients with advanced urothelial carcinoma treated with enfortumab vedotin monotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHiromu HoritaniAKAtsunari KawashimaYIYu Ishizuya

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Horitani et al. (2026) studied this question.

synapsesocial.com/papers/6aa44d691a35fb26f6abeac9https://doi.org/10.1093/jjco/hyag141
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models2016 · 721 citations
  2. 2Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma2021 · 1,236 citations
  3. 3Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer2024 · 1,077 citations
  4. 4Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort2025 · 3 citations
  5. 5Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort2023 · 54 citations